JAK3 and myeloproliferative disorder: Several JAK inhibitors are under investigation for the treatment of hematopoietic diseases, including myeloproliferative neoplasms and autoimmune diseases, including the JAK3-specific Tofacitinib for treatment of rheumatoid arthritis [8, 27].